Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction

Next Previous
X
Search
Trial Profile

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omecamtiv mecarbil (Primary)
  • Indications Chronic heart failure
  • Focus Pharmacokinetics
  • Sponsors Cytokinetics

    • Most Recent Events

    • 29 Aug 2022 Results of meta-analysis of 4 trials (NCT02695420, COSMIC-HF, ATOMIC-AHF & GALACTIC-HF) assessing clinical outcomes of omecamtiv mecarbil in patients with Heart Failure with Reduced Ejection Fraction, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
    • 02 Aug 2017 Results published in a Cytokinetics media release.
    • 15 May 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top